Stock Track | ACADIA Pharmaceuticals Surges 5.24% Pre-Market on Strong Q3 Earnings, Despite Mixed Analyst Reactions

Stock Track11-06

ACADIA Pharmaceuticals (ACAD) stock soared 5.24% in pre-market trading on Thursday, following the company's impressive third-quarter earnings report. The biopharmaceutical firm significantly outperformed analyst expectations, reporting adjusted earnings of 42 cents per share, nearly tripling the mean estimate of 15 cents per share.

The company's revenue also showed strong growth, rising 11.3% to $278.63 million, slightly above the analysts' forecast of $276.47 million. ACADIA reported a quarterly net income of $71.78 million, demonstrating solid financial performance.

Despite the positive earnings results, analyst reactions were mixed. While Needham maintained a Buy rating and raised its price target to $29 from $28, RBC Capital Markets cut its target price to $32 from $34. Morgan Stanley also adjusted its stance, raising the target price to $25 from $24.

The market's enthusiastic response to ACADIA's earnings appears to be outweighing the cautious analyst adjustments. With a median 12-month price target of $29.00, about 23% above its last closing price, ACADIA Pharmaceuticals continues to attract investor interest in the competitive biotechnology and medical research sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170005091?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170005091","market":"us","top_or_hot":-1,"title":"Stock Track | ACADIA Pharmaceuticals Surges 5.24% Pre-Market on Strong Q3 Earnings, Despite Mixed Analyst Reactions","media":"Stock Track","content":"<p>ACADIA Pharmaceuticals (ACAD) stock soared 5.24% in pre-market trading on Thursday, following the company's impressive third-quarter earnings report. The biopharmaceutical firm significantly outperformed analyst expectations, reporting adjusted earnings of 42 cents per share, nearly tripling the mean estimate of 15 cents per share.</p>\n\n<p>The company's revenue also showed strong growth, rising 11.3% to $278.63 million, slightly above the analysts' forecast of $276.47 million. ACADIA reported a quarterly net income of $71.78 million, demonstrating solid financial performance.</p>\n\n<p>Despite the positive earnings results, analyst reactions were mixed. While Needham maintained a Buy rating and raised its price target to $29 from $28, RBC Capital Markets cut its target price to $32 from $34. Morgan Stanley also adjusted its stance, raising the target price to $25 from $24.</p>\n\n<p>The market's enthusiastic response to ACADIA's earnings appears to be outweighing the cautious analyst adjustments. With a median 12-month price target of $29.00, about 23% above its last closing price, ACADIA Pharmaceuticals continues to attract investor interest in the competitive biotechnology and medical research sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ACADIA Pharmaceuticals Surges 5.24% Pre-Market on Strong Q3 Earnings, Despite Mixed Analyst Reactions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ACADIA Pharmaceuticals Surges 5.24% Pre-Market on Strong Q3 Earnings, Despite Mixed Analyst Reactions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ACADIA Pharmaceuticals (ACAD) stock soared 5.24% in pre-market trading on Thursday, following the company's impressive third-quarter earnings report. The biopharmaceutical firm significantly outperformed analyst expectations, reporting adjusted earnings of 42 cents per share, nearly tripling the mean estimate of 15 cents per share.</p>\n\n<p>The company's revenue also showed strong growth, rising 11.3% to $278.63 million, slightly above the analysts' forecast of $276.47 million. ACADIA reported a quarterly net income of $71.78 million, demonstrating solid financial performance.</p>\n\n<p>Despite the positive earnings results, analyst reactions were mixed. While Needham maintained a Buy rating and raised its price target to $29 from $28, RBC Capital Markets cut its target price to $32 from $34. Morgan Stanley also adjusted its stance, raising the target price to $25 from $24.</p>\n\n<p>The market's enthusiastic response to ACADIA's earnings appears to be outweighing the cautious analyst adjustments. With a median 12-month price target of $29.00, about 23% above its last closing price, ACADIA Pharmaceuticals continues to attract investor interest in the competitive biotechnology and medical research sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACAD","symbol_name":"阿卡迪亚","start_time":0,"source_url":"","article_id":"1170005091","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170005091","pubTimestamp":1762437670,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ACADIA Pharmaceuticals (ACAD) stock soared 5.24% in pre-market trading on Thursday, following the company's impressive third-quarter earnings report. The biopharmaceutical firm significantly...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACAD":"阿卡迪亚"},"translate_title":"个股追踪|ACADIA Pharmaceuticals盘前大涨5.24%，因第三季度盈利强劲，尽管分析师反应不一","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACAD":1},"content_text":"ACADIA Pharmaceuticals (ACAD) stock soared 5.24% in pre-market trading on Thursday, following the company's impressive third-quarter earnings report. The biopharmaceutical firm significantly outperformed analyst expectations, reporting adjusted earnings of 42 cents per share, nearly tripling the mean estimate of 15 cents per share.\nThe company's revenue also showed strong growth, rising 11.3% to $278.63 million, slightly above the analysts' forecast of $276.47 million. ACADIA reported a quarterly net income of $71.78 million, demonstrating solid financial performance.\nDespite the positive earnings results, analyst reactions were mixed. While Needham maintained a Buy rating and raised its price target to $29 from $28, RBC Capital Markets cut its target price to $32 from $34. Morgan Stanley also adjusted its stance, raising the target price to $25 from $24.\nThe market's enthusiastic response to ACADIA's earnings appears to be outweighing the cautious analyst adjustments. With a median 12-month price target of $29.00, about 23% above its last closing price, ACADIA Pharmaceuticals continues to attract investor interest in the competitive biotechnology and medical research sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170005091","isCrawlerRequest":true}